ClinicalTrials.gg
CompletedNCT04739774Updated May 5, 2021

Investigation of the Effect of Inhibition of CYP3A4/5 by Itraconazole on the PK of CHF6001 (Tanimilast)

A Phase 1 interventional study of CHF6001 DPI and Itraconazole in Chronic Obstructive Pulmonary Disease, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-05.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing tanimilast in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. tanimilast · Pulmonary Disease, Chronic Obstructive.

Enrollment
10th of 12
24 · median 46
Started
2021
with 3 others
Phase 1
7 of 12
none open now
Registered
8th of 12
by date
Lead sponsor
12 of 12
Chiesi Farmaceutici S.p.A.

Among the 12 studies testing tanimilast in Pulmonary Disease, Chronic Obstructive, this one is the 10th largest by enrollment, is one of 4 that started in 2021, is one of 7 in phase 1, and was the 8th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 12 studies testing tanimilast in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

About tanimilast

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing tanimilast in Pulmonary Disease, Chronic Obstructive as a file.
02

Study summary

The objective of this proposed study is to investigate the pharmacokinetics interaction between CHF6001 as substrate and Itraconazole as inhibitor of CYP3A4/5 in a drug-drug interaction study.

Read the detailed description

This clinical trial is a single centre, single dose Phase I study, with a non-randomized, open label, one sequence cross-over design.

A total of 24 healthy male and female are planned to be included.

Participants will be dosed with CHF6001 before and during co-administration of Itraconazole and will act as their own control. The study will be run with a one-sequence crossover design, where all subjects will be treated with CHF6001 in the first treatment period and CHF6001+Itraconazole in the second treatment period in order to avoid the need of a very long washout from the CYP3A4/5 inhibitor.

Standard safety assessments will be conducted during the Study, including safety blood and urine laboratory tests, vital signs, physical examinations, ECGs and observations of any adverse events. Blood samples will be also collected for PK analysis.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject's written obtained prior to any study-related procedure;
  2. Healthy male and female subjects aged 18-55 years inclusive;
  3. Ability to understand the study procedures, the risks involved and ability to be trained to use the inhalers correctly and to generate sufficient PIF using the In-Check device.
  4. (BMI) between 18,0 and 35,0 kg/m2 extremes inclusive;
  5. Non- or ex-smokers who smoked \< 5 pack years and stopped smoking > 1 year prior to screening;
  6. Good physical and mental status
  7. Vital signs within normal limits
  8. 12 -lead digitalized (12-lead ECG) considered as normal
  9. Pulmonary function test within normal limits
  10. Women of (WOCBP) with fertile male partners: they and/or their partner must be willing to use a highly effective method in addition to a barrier contraception method from the signature of the informed consent and until the follow-up visit. Males with non-pregnant WOCBP partners: they and or/ their partner must be willing to use a highly effective birth control method in addition to the male condom from the signature of the informed consent and until the follow-up visit. Males with pregnant WOCBP partner: they must be willing to use male contraception (condom) from the signature of the informed consent and until the follow-up visit

Exclusion criteria

Exclusion Criteria:

  1. Participation to another clinical trial where drug was received, and last investigations were performed less than 8 weeks prior to screening;
  2. and uncontrolled respiratory, cardiac, hepatic, gastrointestinal, renal, endocrine, metabolic, neurologic, or psychiatric disorders, gastric surgery recent or in the past, and/or impaired gastric motility
  3. Clinically relevant abnormal laboratory values
  4. Abnormal liver enzymes at screening
  5. Subjects with history of breathing problems
  6. Positive HIV1 or HIV2 serology
  7. Positive results from the Hepatitis serology
  8. Blood donation or blood loss (equal or more than 450 ml) less than 2 months prior to screening or before the first dosing;
  9. Positive urine test for cotinine
  10. Documented history of alcohol abuse within 12 months prior to screening or a positive alcohol breath test
  11. Documented history of drug abuse within 12 months prior to screening or a positive urine drug screen
  12. Intake of non-permitted concomitant medications in the predefined period
  13. Presence of any current infection, or previous infection that resolved less than 7 days prior to screening or before the first dosing;
  14. Known intolerance and/or to any of the contained in the formulation used in the trial;
  15. Known allergy to antifungal medicines;
  16. Unsuitable veins for repeated venipuncture;
  17. Heavy caffeine drinker
  18. For females only: pregnant or lactating women. Serum pregnancy test to be performed at screening and urine pregnancy test to be performed before the first dosing;
  19. Subjects receiving treatment with any drug known to have a well-defined potential for hepatotoxicity (e.g. isoniazide, nimesulide, ketoconazole) within the previous 3 months before the screening visit
  20. Subjects using e-cigarettes within 6 months before screening.
  21. Positive documented COVID-19 test before admission
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Treatment R

    Single dose of CHF6001

    Drug: CHF6001 DPI

  • Experimental
    Treatment T

    Single dose of CHF6001 administered after repeated doses of oral Itraconazole

    Drug: CHF6001 DPI · Drug: Itraconazole

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameter (Cmax)

    Peak Plasma Concentration (Cmax) for CHF6001

    Time frame: Over 96 hours after administration in blood

  2. Pharmacokinetic parameter (AUCt)

    Area under the plasma concentration versus time curve (AUCt) for CHF6001

    Time frame: Over 96 hours after administration in blood

Secondary outcomes

  1. Pharmacokinetic parameter (AUC0-96)

    Area under plasma concentration from 0 to 96 hours (AUC0-96) for CHF6001, CHF5956 and CHF6095

    Time frame: Over 96 hours after administration in blood

  2. Pharmacokinetic parameter (AUC0-∞)

    Area under curve extrapolated to infinity (AUC0-∞) for CHF6001, CHF5956 and CHF6095

    Time frame: Over 96 hours after administration in blood

  3. Pharmacokinetic parameter (tmax)

    Time of the maximum plasma concentration (tmax) for CHF6001, CHF5956 and CHF6095

    Time frame: Over 96 hours after administration in blood

  4. Pharmacokinetic parameter (t1/2)

    Terminal half-life (t1/2) for CHF6001, CHF5956 and CHF6095

    Time frame: Over 96 hours after administration in blood

  5. Pharmacokinetic parameter (CL/F)

    Apparent systemic clearance (CL/F) for CHF6001

    Time frame: Over 96 hours after administration in blood

  6. Pharmacokinetic parameter (AUCt)

    Area under the plasma concentration versus time curve (AUCt) for CHF5956 and CHF6095

    Time frame: Over 96 hours after administration in blood

  7. Pharmacokinetic parameter (Cmax)

    Peak Plasma Concentration (Cmax) for CHF5956 and CHF6095

    Time frame: Over 96 hours after administration in blood

07

Study locations

1 site
  • SGS Life Sciences - Clinical Pharmacology Unit Antwerpen
    Antwerp, 2060, Belgium
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Apr 2021, 1 month.

Of 158 industry-sponsored phase 1 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's 1 month is below that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 2 and three quarters within 11.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2021
First posted
Feb 5, 2021
StartActual
Feb 22, 2021
Primary completionActual
Apr 20, 2021
CompletionActual
Apr 26, 2021
Last update
May 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04739774
Responsible party
Sponsor
First posted
Feb 5, 2021
Start date
Feb 22, 2021
Primary completion
Apr 20, 2021
Completion
Apr 26, 2021
Last update
May 5, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tanimilast

Start the discussion